Clinical Cancer Treatment and Drug Resistance: The Interface of the Clinic and the Laboratory
The development of drug resistance is a major roadblock to successful systemic cancer therapy. Although much research has been devoted to this subject in recent years, these efforts have been focused primarily on the molecular mechanisms operative in resistance to chemotherapy. Older, traditional approaches to drug resistance developed from a knowledge of clinical factors such as “sanctuary sites” of metastatic disease and stemmed from empirical observations relating tumor bulk to the likelihood of successful therapy. These observations led to the use of intrathecal chemotherapy for diseases metastatic to the central nervous system, to experimentation with intraperitoneal chemotherapy, and to several theories relating tumor size to chemotherapeutic efficacy. Little attention has been given to the interplay of molecular factors and clinical factors in the development of drug resistance in patients receiving systemic cancer treatment. In this volume we seek to give an overview of known molecular and clinical factors which may result in cancer drug resistance and the probable interplay of these factors in the evolution of resistance in man. Finally, we discuss treatment approaches that hold promise for overcoming the hurdles that exist between current technological possibilities and practical aspects of achieving cancer cure.
KeywordsOvarian Cancer Intraperitoneal Chemotherapy Human Ovarian Cancer Cell Human Ovarian Carcinoma Cell Pleiotropic Drug Resistance
Unable to display preview. Download preview PDF.
- 3.B. A. Chabner, G. A. Curt, and R. L. Fine, Implications of Drug Resistance for Cancer Drug Development, Proc. Am. Assoc. Cancer Res. 26: 390 (1985).Google Scholar
- 5.R. Tram, P. Cusick, J. Wilson, and M. Merinus, Mismatch Repair of cis-Diamminedichloroplatinum II (CDDP) Induced DNA Damage in E. cola, Abstracts, Proc. 4th Internatl. Conf. on Environmental Mutagens (1985).Google Scholar
- 6.E. Reed, B. Behrens, S. H. Yuspa, M. C. Poirier, T. Hamilton, and R. F. Ozols, Differences in Cisplatin-DNA Adduct Formation in Sensitive and Resistant Sublines of Human Ovarian Cancer Cells, Proc. Am. Assoc. Cancer Res., submitted for publication (1986).Google Scholar
- 10.T. C. Hamilton, M. A. Winker, K. G. Louie, G. Batist, B. C. Behrens, T. Tsuruo, K. R. Grotzinger, W. M. McKay, R. C. Young, and R. F. Ozols, Augmentation of Adriamycin, Melphalan, and Cisplatin Cytotoxicity in Drug-resistant and -sensitive Human Ovarian Carcinoma Cell Lines by Buthionine and Sulfoxamine Mediated Glutathione Depletion, Biochem. Pharm. 34: 2583 (1985).PubMedCrossRefGoogle Scholar
- 21.R. F. Ozols and R. C. Young, Patterns of Failure of Chemotherapy in Gynecologic Malignancy: Implications for Future Clinical Trials, Cancer Treat. Symposia 2: 233 (1983).Google Scholar
- 22.P. L. Kornblith, M. D. Walker, and J. R. Cassady, Treatment of Metastatic Cancer to Brain, in: “Cancer: Principles and Practice of Oncology,” V. T. DeVita, S. Hellman, and S. A. Rosenberg, eds., Lippincott, Philadelphia, (1985).Google Scholar
- 23.D. G. Poplack, J. R. Cassady, and P. A. Pizzo, Leukemias and Lymphomas of Childhood, in: “Cancer: Principles and Practice of Oncology,” V. T. DeVita, S. Hellman, and S. A. Rosenberg, eds., Lippincott, Philadelphia, (1985).Google Scholar
- 24.E. Reed, S. H. Yuspa, L. A. Zwelling, R. F. Ozols, and M. C. Poirier, Quantitation of cis-Diamminedichloroplatinum II (cisplatin)-DNAIntrastrand Adducts in Testicular and Ovarian Cancer Patients Receiving Cisplatin Chemotherapy, J. Clin. Invest., in press (1986).Google Scholar
- 26.S. A. Rosenberg, M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chong, S. E. Ettinghausen, Y. L. Matory, J. M. Skibber, E. Shiloni, J. T. Vetto, C. A. Seipp, C. Simpson, and C. M. Reichert, Observations on the Systemic Administration of Autologous Lymphokine-activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer, N. Eng. J. Med. 313: 1485 (1985).CrossRefGoogle Scholar
- 27.R. H. Wiltrout and R. R. Salup, Combined Modality Approach to Treatment of Murine Renal Cancer, in: “Proceedings of the Congress on Natural Immunity and Therapy of Cancer and Other Diseases,” E. Lotzova, ed., S. Karger, A.G. Basel, in press (1986).Google Scholar